SureTrader SureTrader SureTrader
Home > Boards > US OTC > Medical - Drugs >

Cellceutix Corporation (CTIX)

Add CTIX Price Alert      Hide Sticky   Hide Intro
Moderator: NotAsBigKahuna, BooDog, TOB, sox040713, Astavakra, TheHound
Search This Board:
Last Post: 1/17/2017 6:19:53 PM - Followers: 699 - Board type: Free - Posts Today: 236

Cellceutix Corporation (CTIX)
Company Address:
100 Cumming Center, Suite 151-B
Beverly, MA 01915
Phone: 978-236-8717
Fax:  978-921-6564
Email:  [email protected]
About Cellceutix: 

Headquartered in Beverly, Massachusetts, Cellceutix is a publicly traded company under the symbol “CTIX”. Cellceutix is a clinical stage biopharmaceutical company developing innovative therapies in multiple diseases. Cellceutix believes it has a world-class portfolio of compounds and is now engaged in advancing its compounds and seeking strategic partnerships. Cellceutix’s anti-cancer drug Kevetrin concluded a Phase 1 clinical trial at Harvard Cancer Centers’ Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center, and Cellceutix is now preparing its FDA application for a Phase 2 ovarian cancer study. In the laboratory, Kevetrin has shown to induce activation of p53, often referred to as the “Guardian Angel Gene” due to its crucial role in controlling cell mutations. Cellceutix is in a Phase 2 clinical trial with its novel compound Brilacidin-OM for the prevention of Oral Mucositis in patients with head and neck cancer. Brilacidin-OM, a defensin mimetic compound, has shown in an animal model to reduce the occurrence of severe ulcerative oral mucositis by more than 94% compared to placebo. Cellceutix’s anti-psoriasis drug Prurisol completed a Phase 2 trial. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Cellceutix’s lead antibiotic, Brilacidin, has completed a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infections, or ABSSSI. Top-line data have shown a single dose of Brilacidin to deliver comparable clinical outcomes to the FDA-approved seven-day dosing regimen of daptomycin. Brilacidin has the potential to be a single-dose therapy for certain multi-drug resistant bacteria (Superbugs). Brilacidin is also being evaluated in a Phase 2 Proof-of-Concept trial as a novel treatment for Ulcerative Proctitis. Cellceutix has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. More information is available on the Cellceutix web site at 


Ongoing Human Trials:
Product Pipeline:


FDA Designations:

Upcoming Milestones:

Recent News and Press Releases:

Seeking Alpha focus articles on CTIX:

A randomized, double-blind study comparing single-dose and short-course brilacidin to daptomycin in the treatment of acute bacterial skin & skin structure infections (ABSSSI)

Synthetic novel host defense protein mimetics for the treatment of Gram-negative bacterial infections

SEC Filings (CIK:0001355250):

Transfer Agent:
West Coast Stock Transfer, Inc.
721 N. Vulcan Ave. Ste. 205
Encinitas, CA 92024
(619) 664-4780 p
(760) 452-4423 f
[email protected]

Share Structure:  See SEC filing link above for current share structure

Cellceutix IP - Patent Filings:



Publication number US8338454 B2
Publication type Grant
Application number US 12/780,132
Publication date Dec 25, 2012
Filing date May 14, 2010
Priority date May 20, 2009
Also published as CA2762427A1, CN102438612A, EP2432464A2, US20100298374, US20130245062, WO2010135170A2, WO2010135170A3, Less «6 More »
Publication number 12780132, 780132, US 8338454 B2, US 8338454B2, US-B2-8338454, US8338454 B2, US8338454B2
Inventors Krishna Menon
Original Assignee Cellceutix Corporation
Export Citation BiBTeX, EndNote, RefMan
Patent Citations (6), Non-Patent Citations (41), Referenced by (1), Classifications (42)
External Links: USPTO, USPTO Assignment, Espacenet

Investor Relations:  [email protected]

Following is a WEEKLY chart:


All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
Also, keep in mind that moderators may or may not have a position in said stock.  Being a moderator isn’t a sign of endorsement.
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement:

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
CTIX News: Amended Statement of Ownership (sc 13g/a) 01/04/2017 03:58:28 PM
CTIX News: Current Report Filing (8-k) 11/15/2016 06:25:29 AM
CTIX News: Quarterly Report (10-q) 11/09/2016 06:06:41 AM
CTIX News: Amended Annual Report (10-k/a) 10/28/2016 05:02:25 PM
CTIX News: Current Report Filing (8-k) 09/15/2016 08:01:38 AM
#168566  Sticky Note We can fight back by filing a complaint sox040713 01/17/17 02:02:05 PM
#168245  Sticky Note About Kevetrin should be made sticky: Blue Fin 01/13/17 11:28:38 AM
#165552  Sticky Note B-UP Due Diligence sox040713 12/09/16 12:17:52 PM
#165491  Sticky Note New Oral Psoriasis Drug Tops Cellceutix Catalysts $CTIX http://www.seekingalpha. Matagordaville 12/08/16 04:55:12 PM
#165310  Sticky Note News: Cellceutix Phase 2 Trial Dose Escalates in BooDog 12/07/16 07:40:13 AM
#117003  Sticky Note Cellceutix released efficacy data for Kevetrin, its cancer TOB 08/09/15 03:05:24 PM
#168658   ...not above the law...because CTIX did not go Justfactsmam 01/17/17 06:30:06 PM
#168657   Any law firm would be extremely foolish to Areader 01/17/17 06:24:46 PM
#168656   Don't be so quick to jump to conclusions. scottsmith 01/17/17 06:19:53 PM
#168655   Financing is THE concern. I've been looking noretreat 01/17/17 06:09:21 PM
#168653   Oh yeah govorchin 01/17/17 05:53:54 PM
#168652   FINRA short sales of CTIX AlanC 01/17/17 05:47:17 PM
#168651   You do not know for a FACT that taas 01/17/17 05:44:14 PM
#168650   Mako and others like him foolishly rely on frrol 01/17/17 05:39:47 PM
#168649   SA it would seem has a lot more NotRichYet2 01/17/17 05:34:53 PM
#168648   I know for a fact bp isn't behind scottsmith 01/17/17 05:29:41 PM
#168647   Here we go again. Sullivan filing papers, Rosen JTORENCE 01/17/17 05:28:34 PM
#168646   Everyone's focus seems to be on Mako, but 4theduration 01/17/17 05:24:34 PM
#168645   Nice to have Karen CA back! firefight 01/17/17 05:24:11 PM
#168644   I look forward to Sullivan/Ashcroft/CTIX exposing the criminals AlanC 01/17/17 05:20:50 PM
#168643   Enrollment has been completed in the second cohort BooDog 01/17/17 05:18:35 PM
#168642   F the shorts and all the greedy pricks eventhelosers 01/17/17 05:17:16 PM
#168641   Mako is neither wise nor prudent. I Detonate 01/17/17 05:15:30 PM
#168640   He's been careful, but a partnership or sale Rdunn88 01/17/17 05:10:36 PM
#168639   Wow. Congrats. I wish I had DaubersUP 01/17/17 05:05:36 PM
#168638   MAKO has ZERO fear! It just blows my tombrady12nh 01/17/17 05:04:43 PM
#168637   Another 50K share add today. I love days thumbgreen 01/17/17 05:01:41 PM
#168636   History shows Leo has been very careful with KarinCA 01/17/17 04:52:33 PM
#168635   Whenever someone looks at a hit piece they KarinCA 01/17/17 04:48:49 PM
#168634   There's been rumors that Leo may of had Rdunn88 01/17/17 04:47:47 PM
#168633   I agree Karin. There are simply too many BioTechMaven 01/17/17 04:43:55 PM
#168632   I'm curious, do you have any reason to KarinCA 01/17/17 04:40:19 PM
#168631   The absurdity of the panic is beyond crazy. BioTechMaven 01/17/17 04:36:33 PM
#168630   Even though the price fell a bit overall Stockstuffer83 01/17/17 04:34:54 PM
#168629   Leo should seriously take a look at any Rdunn88 01/17/17 04:30:21 PM
#168628   Correct, and agree 100%. Also, as mentioned by TheBunny 01/17/17 04:27:45 PM
#168627   i wonder what big pharma is behind these govorchin 01/17/17 04:22:14 PM
#168626   Cost of Maco hit piece today 10,048,000. and Blue Fin 01/17/17 04:19:02 PM
#168625   My 2 cents. Citrati 01/17/17 04:17:01 PM
#168624   Please do not look at sa piece. Jhawker 01/17/17 04:12:46 PM
#168623   SA Editor released it and price dropped from DaubersUP 01/17/17 04:09:29 PM
#168622   Down 7.7% at close. Ouch that hurts! How sox040713 01/17/17 04:07:35 PM
#168621   That doesn't help CTIX's situation what's done 3 Rdunn88 01/17/17 04:05:08 PM
#168620   Sullivan wrote the response groton68 01/17/17 04:01:15 PM
#168619   New article on sa youssef 01/17/17 03:58:49 PM
#168618   After reading this, I have to think that Spebenz 01/17/17 03:58:13 PM
#168617   It's hard to see how the price drops TheDane 01/17/17 03:51:39 PM
#168616   Cellceutix Strongly Denounces Criminal Enterprise Mako Research, Who sox040713 01/17/17 03:50:17 PM
#168615   I think it might get the AG's attention sox040713 01/17/17 03:45:20 PM
#168614   I'm pretty sure they've been the ones holding Ringrock 01/17/17 03:39:57 PM
#168613   Seems pretty clear that the markets think Mako DoubleJ23 01/17/17 03:33:13 PM
#168612   The way SA editing works these days, I'm KarinCA 01/17/17 03:26:56 PM
#168611   thanks for the belly laugh... Nope, but this may Ringrock 01/17/17 03:23:26 PM
#168610   CTIX response posted on SA: Blue Fin 01/17/17 03:23:23 PM
#168609   A haiku dedicated to the CEO: scottsmith 01/17/17 03:21:09 PM
#168608   Ask is very thin to 1.20 mantis 01/17/17 03:20:55 PM